Related Experiment Video
Updated: Oct 26, 2025

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification
Published on: December 3, 2016
Pycnodysostosis: A Growth Hormone Responsive Skeletal Dysplasia
Hafsa Omer Sulaiman1, Nandu Kumar Sidramappa Thalange2
1St. George's University of London, London, UK.
Insights
Growth hormone (GH) therapy is effective for children with pycnodysostosis, a rare genetic disorder. Early treatment improves height and body proportions, offering significant benefits for affected children.
Area of Science:
- Pediatric Endocrinology
- Skeletal Dysplasias
- Genetics
Background:
- Pycnodysostosis is a rare genetic disorder characterized by skeletal abnormalities.
- Growth hormone (GH) deficiency is a frequent comorbidity in pycnodysostosis, often linked to pituitary hypoplasia.
Observation:
- A 22-month-old boy with pycnodysostosis presented with severe short stature ( -4.05 SDS).
- Genetic analysis revealed a CTSK mutation, and MRI confirmed pituitary hypoplasia.
Findings:
- The patient showed biochemical responsiveness to growth hormone (GH) therapy via an insulin-like growth factor generation test.
- GH treatment resulted in significant height improvement (to -2.25 SDS) and an annualized growth velocity of 9.65 cm/y over 18 months.
Implications:
- GH therapy is a crucial consideration for managing short stature in pycnodysostosis.
- Initiating GH treatment at a younger age maximizes therapeutic benefits and improves long-term outcomes.
Objective:
Pycnodysostosis is commonly associated with growth hormone (GH) deficiency and responds well to GH therapy with achievement of normal or near-normal height and restoration of body proportions.
Case Report:
A 22-month-old extremely short (-4.05 height standard deviation score) disproportionate boy with skeletal dysplasia presented to clinic. Skeletal survey, genetic panel, magnetic resonance imaging, and an insulin-like growth factor generation tests were performed.
Results:
Skeletal survey showed increased bone density with classic features of pycnodysostosis, subsequently confirmed to be due to a deleterious homozygous frameshift mutation in CTSK. Uniquely among skeletal dysplasias, GH deficiency is a common association, secondary to pituitary hypoplasia. Magnetic resonance imaging confirmed pituitary hypoplasia and he subsequently underwent an insulin-like growth factor generation test that demonstrated biochemical responsiveness to GH therapy. This was thought to be safer than a classic GH stimulation test, in view of his very small size. Subsequently, his height has markedly improved on GH therapy. His height is now -2.25 SD, with an annualized growth velocity of 9.65 cm/y over a period of 18 months .
Conclusion:
It is important to consider GH therapy in children with pycnodysostosis, with the greatest benefit seen in children started at a young age.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Growth of Cartilage and Bone Tissue
Signs of Puberty
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Bone Formation by Endochondral Ossification
Nature and Nurture

